IN2014MU01128A - - Google Patents

Download PDF

Info

Publication number
IN2014MU01128A
IN2014MU01128A IN1128MU2014A IN2014MU01128A IN 2014MU01128 A IN2014MU01128 A IN 2014MU01128A IN 1128MU2014 A IN1128MU2014 A IN 1128MU2014A IN 2014MU01128 A IN2014MU01128 A IN 2014MU01128A
Authority
IN
India
Prior art keywords
composition containing
maturation
delaying
diabetes
administering
Prior art date
Application number
Inventor
Deshpande Dr Jayant
J Shankaranarayanan
Original Assignee
Omniactive Health Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US15/300,210 priority Critical patent/US20170143646A1/en
Priority to JP2017501531A priority patent/JP2017511380A/en
Priority to IN1128MU2014 priority patent/IN2014MU01128A/en
Priority to SG11201607996SA priority patent/SG11201607996SA/en
Priority to KR1020167030397A priority patent/KR20160140859A/en
Priority to AU2015237806A priority patent/AU2015237806A1/en
Priority to PCT/IB2015/052248 priority patent/WO2015145389A2/en
Priority to CN201580017290.3A priority patent/CN106163536A/en
Application filed by Omniactive Health Technologies Ltd filed Critical Omniactive Health Technologies Ltd
Priority to CA2943921A priority patent/CA2943921A1/en
Priority to MX2016012625A priority patent/MX2016012625A/en
Priority to EP15717249.5A priority patent/EP3122339A2/en
Publication of IN2014MU01128A publication Critical patent/IN2014MU01128A/en
Priority to IL248016A priority patent/IL248016A0/en
Priority to PH12016501914A priority patent/PH12016501914A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)

Abstract

The present invention provides use of composition containing molecular dispersions of lipophilic nutrients for delaying the development and maturation of eye related complications of diabetes by administering a composition containing lipophilic nutrients. More particularly, the present invention relates to a method of delaying the development and maturation of eye related complications of diabetes by administering a composition containing lutein and its isomers, lutein ester, zeaxanthin isomers, turmeric extract, curcumin or curcuminoids, derived from plant extract/oleoresin containing xanthophylls/ xanthophylls esters which are safe for human consumption and are particularly useful as dietary supplements for nutrition and health promoting benefits.
IN1128MU2014 2014-03-28 2015-03-26 IN2014MU01128A (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
PCT/IB2015/052248 WO2015145389A2 (en) 2014-03-28 2015-03-26 Effect of lipophilic nutrients on diabetic eye diseases
IN1128MU2014 IN2014MU01128A (en) 2014-03-28 2015-03-26
SG11201607996SA SG11201607996SA (en) 2014-03-28 2015-03-26 Effect of lipophilic nutrients on diabetic eye diseases
KR1020167030397A KR20160140859A (en) 2014-03-28 2015-03-26 Effect of lipophilic nutrients on diabetic eye diseases
AU2015237806A AU2015237806A1 (en) 2014-03-28 2015-03-26 Effect of lipophilic nutrients on diabetic eye diseases
US15/300,210 US20170143646A1 (en) 2014-03-28 2015-03-26 Effect of lipophilic nutrients on diabetic eye diseases
CN201580017290.3A CN106163536A (en) 2014-03-28 2015-03-26 The lipophilic nutrients effect to diabetic oculopathy
JP2017501531A JP2017511380A (en) 2014-03-28 2015-03-26 Effects of fat-soluble nutrients on diabetic eye diseases
CA2943921A CA2943921A1 (en) 2014-03-28 2015-03-26 Effect of lipophilic nutrients on diabetic eye diseases
MX2016012625A MX2016012625A (en) 2014-03-28 2015-03-26 Effect of lipophilic nutrients on diabetic eye diseases.
EP15717249.5A EP3122339A2 (en) 2014-03-28 2015-03-26 Effect of lipophilic nutrients on diabetic eye diseases
IL248016A IL248016A0 (en) 2014-03-28 2016-09-25 Effect of lipophilic nutrients on diabetic eye diseases
PH12016501914A PH12016501914A1 (en) 2014-03-28 2016-09-27 Effect of lipophilic nutrients on diabetic eye diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1128MU2014 IN2014MU01128A (en) 2014-03-28 2015-03-26

Publications (1)

Publication Number Publication Date
IN2014MU01128A true IN2014MU01128A (en) 2015-10-02

Family

ID=54196517

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1128MU2014 IN2014MU01128A (en) 2014-03-28 2015-03-26

Country Status (13)

Country Link
US (1) US20170143646A1 (en)
EP (1) EP3122339A2 (en)
JP (1) JP2017511380A (en)
KR (1) KR20160140859A (en)
CN (1) CN106163536A (en)
AU (1) AU2015237806A1 (en)
CA (1) CA2943921A1 (en)
IL (1) IL248016A0 (en)
IN (1) IN2014MU01128A (en)
MX (1) MX2016012625A (en)
PH (1) PH12016501914A1 (en)
SG (1) SG11201607996SA (en)
WO (1) WO2015145389A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017137294A (en) * 2016-01-29 2017-08-10 静岡県公立大学法人 Composition for delivery of zingiberaceae plant extract
US20190125694A1 (en) * 2016-04-16 2019-05-02 Omniactive Health Technologies Limited Method for treatment of visual stress conditions and compositions used therein
US20180168182A1 (en) * 2016-12-21 2018-06-21 Muhammed Majeed Chewable compositions containing curcuminoids and their method of preparation
WO2019050542A1 (en) * 2017-09-11 2019-03-14 Verdure Sciences Methods and compositions for the treatment of retinal, neurological and other related diseases
CN108421020A (en) * 2018-05-29 2018-08-21 李玉梅 It is a kind of to be used to treat Ginger P.E of diabetic retinopathy and its preparation method and application
US11135179B1 (en) 2018-12-28 2021-10-05 QH Holdings (Oregon), Inc. Eye health supplement
US11141386B1 (en) 2018-12-28 2021-10-12 QH Holdings (Oregon), Inc. Eye health supplement with curcumin
WO2020217258A1 (en) * 2019-04-26 2020-10-29 Jeyakodi Shankaranarayanan Bioaccessibile compositions of lipophilic compounds and process thereof
EP3967148A4 (en) * 2019-05-06 2022-12-21 Shenzhen Linpingxijing Vision Technology Co., Ltd Eye-nourishing and eyesight-improving herbal candy containing nutrients for human eye lens and retinal photosensitive cells
CN112006282A (en) * 2020-09-04 2020-12-01 北京瑞济善健康科技有限公司 Composition for repairing diabetic complications and preparation method and application thereof
DE102022122731A1 (en) * 2022-09-07 2024-03-07 Ruma Gmbh Metabolizable control markers for endogenous urine labeling

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998753A (en) * 1974-08-13 1976-12-21 Hoffmann-La Roche Inc. Water dispersible carotenoid preparations and processes thereof
US6737535B2 (en) 2002-06-05 2004-05-18 Kancor Flavours And Extracts Limited Trans-lutein enriched xanthophyll ester concentrate and a process for its preparation
US6743953B2 (en) 2002-08-26 2004-06-01 Kancor Flavours & Extracts Ltd. Process for the preparation of xanthophyll crystals
US20060088574A1 (en) * 2004-10-25 2006-04-27 Manning Paul B Nutritional supplements
WO2008063513A2 (en) * 2006-11-13 2008-05-29 Trustees Of Columbia University In The City Of New York Selective proteasome inhibitors for treating diabetes
US20080181972A1 (en) * 2007-01-29 2008-07-31 Valentina Amico Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health
US8163312B2 (en) 2008-09-22 2012-04-24 Innoveda Biological Solutions (P) Ltd. Herbal formulation for prevention and treatment of diabetes and associated complications
US20120114637A1 (en) 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
KR101479821B1 (en) * 2009-09-02 2015-01-06 옴니액티브 헬스 테크놀로지스 리미티드 A xanthophyl composition containing macular pigmemts and a process for its preparation
US20110300246A1 (en) * 2010-06-03 2011-12-08 Qinheng Huang Herbal Extracts for Treatment of Diabetic Complications and Oxidative Stress
PT2433640T (en) 2010-09-24 2020-04-03 Omnivision Gmbh Composition comprising sod, lutein and zeaxanthin
CN102178925A (en) 2011-04-25 2011-09-14 崔晓廷 Novel eyesight protective agent lutein ophthalmic preparation
CN102225087A (en) * 2011-06-09 2011-10-26 雷爱林 Xanthophyll compound preparation with powerful eye-protecting effect
EP2978418A1 (en) * 2013-03-28 2016-02-03 OmniActive Health Technologies Limited Neuroprotective effect of carotenoids in brain
CN103238902B (en) * 2013-05-23 2014-12-03 云南瑞宝生物科技有限公司 Juice powder and preparation method thereof

Also Published As

Publication number Publication date
CN106163536A (en) 2016-11-23
US20170143646A1 (en) 2017-05-25
MX2016012625A (en) 2017-01-09
SG11201607996SA (en) 2016-11-29
PH12016501914A1 (en) 2017-01-09
JP2017511380A (en) 2017-04-20
AU2015237806A1 (en) 2016-10-20
CA2943921A1 (en) 2015-10-01
EP3122339A2 (en) 2017-02-01
WO2015145389A3 (en) 2015-11-26
KR20160140859A (en) 2016-12-07
WO2015145389A2 (en) 2015-10-01
IL248016A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
IN2014MU01128A (en)
AR103260A1 (en) IMMUNE MODULATION
PH12015502238A1 (en) Neuroprotective effect of carotenoids in brain
ECSP17043318A (en) COMPOSITION CONTAINING CHITIN AND DIGERIBLE PROTEINS
BR112018008777A2 (en) method for isolating an enriched fraction of small mRNA molecules from a sample of fungi and / or plants, small mRNA molecules, food and / or food additive and / or dietary supplement and / or nutraceutical product, method for producing a second nutraceutical food and / or pharmaceutical and cosmetic composition
BR112018003745A2 (en) compositions comprising a urolithin compound
CL2017000475A1 (en) Compositions for cosmetic formulation comprising a mixture selected from murumuru butter, ucuuba butter, brazilian-nut oil, passion fruit oil, cupuassu butter, assai oil and/or nhandiroba oil and/or esters thereof, as well as the use of a mixture for the preparation of a cosmetic
BR112017013004A2 (en) fried product obtained from a composition for a fried product, use of a microalgae flour as a fat substitute and method of preparing a fried product
EP3197857A4 (en) Fatty acid composition and method for fortifying nutritional products with fatty acids
MX2016016995A (en) Composition containing phytic acid, magnesium and polyphenols for the treatment or prevention of renal lithiasis.
EP3185695A4 (en) Preparation of soy protein products ("s810")
MX2020002458A (en) Prevention and/or treatment of neurodegenerative disease.
WO2016080796A3 (en) Pharmaceutical composition, containing sesquiterpene compound, for preventing or treating stat3-mediated diseases, and use thereof
CR20150478A (en) METHOD FOR THE TREATMENT AND CONTROL OF POST-COLLECTION DISEASES OF FRUITS AND VEGETABLES AND COMPOSITIONS THAT INCLUDE NATURAL EXTRACTS AND PHYTOFORTIFICATING FORMULATIONS AND / OR FUNGICIDES TO APPLY IN SUCH METHOD.
BR112017003945A2 (en) edible fat composition
NZ713235A (en) Product and method for improving bioavailability of therapeutic compounds
PH12017500203B1 (en) Nutritional composition for use in promoting gut and/or liver maturation and/or repair
EP3220933A4 (en) Method of increasing levels of omega-3 fatty acids in beef products by administration of a grass and algae diet
BR112017003066A2 (en) drink composition containing powdered ginseng and method for its preparation
MX2017007230A (en) Compositions and methods comprising medium chain triglycerides for treatment of epilepsy.
PH12017500740A1 (en) Nutritional supplements containing a peptide component and uses thereof
BR112018008964A2 (en) method to induce satiety
Santini et al. Nutraceuticals recovery from tomato processing waste and by-products: lycopene
ES2542163R2 (en) PROCEDURE FOR OBTAINING GERMINATED INTEGRAL RICE GRAINS AND PRODUCTS DERIVED FROM THE SAME UNDERSTANDING COMPOUNDS BIOLOGICALLY ACTIVE
CO2018014231A2 (en) Method for processing plant material